Jazz Pharmaceuticals’ planned $7.2 billion takeover of United Kingdom-based GW Pharmaceuticals could kick off a wave of deal-making between pharma and medical cannabis companies, analysts and industry sources say. But rather than all cannabis pro…
David Kideckel
Will GW’s multibillion-dollar sale ‘open floodgates’ to pharma-cannabis deal-making?
Jazz Pharmaceuticals’ planned $7.2 billion takeover of United Kingdom-based GW Pharmaceuticals could kick off a wave of deal-making between pharma and medical cannabis companies, analysts and industry sources say. But rather than all cannabis pro…